Primary Immune Thrombocytopenia
Conditions
Interventions
Short-course glucocorticoid group:Glucocorticoid decreased within 1 week
Routine glucocorticoids group:Glucocorticoid doses gradually decrease
Short-course low dose glucocorticoid maintenance group:Small doses of glucocorticoids maintained
Sponsors
Department of Hematology, the Second Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Patients who sign the informed consent, and fully understand and complie with the requirements of the study protocol; 2) Aged >=18 years old, male or female; 3) Multiple laboratory tests showed thrombocytopenia; 4) No or only mild enlargement of spleen; 5) The number of megakaryocytes in bone marrow examination is increased or normal, and there is maturation disorder; 6) Except all kinds of secondary thrombocytopenia; 7) Newly diagnosed ITP patients (within 3 months after diagnosis); 8) ITP patients with complete response (platelet >=100x10^9/L) after initial hormone therapy.
Exclusion criteria
Exclusion criteria: 1) Patients with secondary thrombocytopenia; 2) If the initial treatment is intravenous immunoglobulin, patients with ineffective hormone therapy should be excluded; 3) Pregnant and lactating women; 4) Patients with a history of allergy to adrenocorticosteroids; 5) Patients who have participated in clinical trials of other new drugs within 3 months; 6) Abnormal liver and kidney function: defined as serum transaminase and bilirubin >=1.5 times the upper limit of normal value, creatinine exceeds the upper normal limit; 7) Antibody of second liver surface antigen, hepatitis c, HIV antibody (I+II), syphilis antibody positive; 8) Patients complicated with diabetes, hypertension, glaucoma, digestive tract ulcer, herpes zoster, lung infection and other diseases that are not suitable for glucocorticoid maintenance treatment; 9) Patients with poor compliance; 10) Unable to take contraceptive measures during the test; 11) The investigator considers that the patient should not participate in this study under any other circumstances.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| platelets; | — |
Countries
China
Contacts
Public ContactZeping Zhou
Department of Hematology, the Second Affiliated Hospital of Kunming Medical University
Outcome results
None listed